Inve India ▾

Suven Life Sciences share price & results

Suven Life Sciences Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q3 FY20
Ownership as of
Sept 2026

India's only pure-play CNS-focused NCE drug discovery company, developing new molecules for Alzheimer's, depression and sleep disorders.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue4.0 ₹ crore+100.0% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin-588.0 %+161.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit-16.0 ₹ crore—Quarterly, as filedQuarter to Jun 2026Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown.
Return on equityUnavailable+5.8 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Not in the analysed materials. No older figure is substituted.
Free cash flow marginUnavailable—Fiscal yearFY ending Mar 2026Not in the analysed materials. No older figure is substituted.
Revenue growth (YoY)25.00 %+41.7 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

2 of 3 judged targets kept · 8 open · verdicts reflect calls analysed to Q3 FY20.

Suven Life Sciences Limited management guidance track record on Inve: 11 targets tracked across analysed earnings calls (2 achieved, 1 missed, 8 open).

TargetOriginal wordingSaidLatest callVerdict
SUVN-502 Data Release TimelineJuly 2019
Call transcript, Q3 FY19 · 6 Feb 2019		Q3 FY19Q3 FY20:we have a big disappointment with respect to the SUVN-502... it did not make the final end point
Call transcript, Q3 FY20 · 14 Feb 2020		Achieved
FY20 Bottom-line Growth20-25%
Call transcript, Q3 FY19 · 6 Feb 2019		Q3 FY19Q3 FY20:Not addressed in the call.
Call transcript, Q3 FY20 · 14 Feb 2020		Ghosted
FY20 Revenue Growth15%
Call transcript, Q3 FY19 · 6 Feb 2019		Q3 FY19Q3 FY20:So overall we will be giving a 20% to 22% growth compared to last year.
Call transcript, Q3 FY20 · 14 Feb 2020		Revised Up

Source: Inve Guidance Tracker for Suven Life Sciences Limited · to Q3 FY20

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

1 of Suven Life Sciences Limited's 11 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 8 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹261.4 −0.23% · −₹0.6

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +30.9% 1Y

₹200₹300₹400Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26

1Y: ₹199.66 on 24 Oct 2025 → ₹261.4. High ₹392.05 (31 Aug 2026), low ₹126.65 (23 Mar 2026).

Previous close
₹262
Market cap
₹7.4k Cr
52-week range
₹126.65 – ₹392.05
One year
+33.32%
Return on equity (FY ending Mar 2026)
-81.60%

Overview

Symbol
NSE:SUVEN
Exchange
NSE
Currency
INR

What Suven Life Sciences Limited does

Based on the company's own presentations, annual report and earnings calls.

Suven Life Sciences discovers and develops New Chemical Entities (NCEs) targeting Central Nervous System (CNS) disorders such as Alzheimer's disease, schizophrenia, depression, narcolepsy and cognitive disorders. It does not manufacture or sell any approved drug; instead it earns through out-licensing, partnership/collaboration deals and eventual commercialisation of its pipeline molecules once they clear clinical trials. Its wholly-owned US subsidiary, Suven Neurosciences Inc. (Delaware), runs the clinical development and commercialisation of its NCE molecules in the United States. The company was formed via the 2020 demerger that hived off its earlier CRAMS (contract research and manufacturing) business into a separate listed entity, leaving Suven to focus solely on CNS drug discovery and development.

CNS molecule pipeline
13 molecules
Molecules in clinical trial phase
5 molecules
Molecules in Phase 2/3 clinical trials
3 molecules
Global patents held
2,850+ (expiring 2035 and beyond)
Market position
India's only CNS-focused, NCE (New Chemical Entity) developer
US clinical subsidiary
Suven Neurosciences, Inc. (Delaware, USA), est. 2015
Founded 1989Headquarters Hyderabad, Telangana, IndiaEmployees 132 (FY2024-25 (Annual Report) Company website

Your own record

Start an Inve Case for Suven Life Sciences Limited

Free account: one company. Everything above stays public.

Write why you follow Suven Life Sciences Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Suven Life Sciences Limited

Guides on how to read this kind of business and the numbers that matter.